StreetInsider.com News Articles

Form 3 PLIANT THERAPEUTICS, For: Jul 09 Filed by: Iannone Robert

Mon, 13 Jul 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260713/26762861.html

Form 3 PLIANT THERAPEUTICS, For: Jul 09 Filed by: Iannone Robert

Mon, 13 Jul 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260713/26762861.html

Form 4 PLIANT THERAPEUTICS, For: Jul 09 Filed by: Borellini Flavia

Mon, 13 Jul 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260713/26762855.html

Form 4 PLIANT THERAPEUTICS, For: Jul 09 Filed by: Borellini Flavia

Mon, 13 Jul 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260713/26762855.html

Form 4 PLIANT THERAPEUTICS, For: Jul 09 Filed by: Iannone Robert

Mon, 13 Jul 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260713/26762857.html

Form 4 PLIANT THERAPEUTICS, For: Jul 09 Filed by: Iannone Robert

Mon, 13 Jul 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260713/26762857.html

Form 3 PLIANT THERAPEUTICS, For: Jul 09 Filed by: Borellini Flavia

Mon, 13 Jul 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260713/26762858.html

Form 3 PLIANT THERAPEUTICS, For: Jul 09 Filed by: Borellini Flavia

Mon, 13 Jul 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260713/26762858.html

Form 8-K PLIANT THERAPEUTICS, For: Jul 09

Mon, 13 Jul 2026 16:25:00 -0400

si-local-file:///var/storage/secattach/20260713/26762730.html

Form 8-K PLIANT THERAPEUTICS, For: Jul 09

Mon, 13 Jul 2026 16:25:00 -0400

si-local-file:///var/storage/secattach/20260713/26762730.html

Pliant Therapeutics adds two directors with oncology backgrounds

Mon, 13 Jul 2026 08:30:17 -0400

Pliant Therapeutics, Inc. (Nasdaq: PLRX) announced the appointments of Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to its Board of Directors, according to a press release issued July 13, 2026.

Dr. Borellini has more than 25 years of experience in pharmaceutical and biotechnology executive roles, with a focus on targeted oncology drug development. She most recently served as Chief Executive Officer of Acerta Pharma, where she oversaw the development and approval of Calquence (acalabrutinib). She previously held senior positions at AstraZeneca, including Global Franchise Head of Hematology, and led the development of Tagrisso (osimertinib). Earlier in her career at Genentech,

Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to Board of Directors

Mon, 13 Jul 2026 08:30:00 -0400

Appointments bring global oncology drug development experience
and deepen Board’s operational and regulatory expertise

SOUTH SAN FRANCISCO, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced the appointments of Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to its Board of Directors.

"On behalf of the Board of Directors, I am pleased to welcome Flavia and Robert, two accomplished biopharmaceutical leaders whose broad expertise in global oncology drug development will be of tremendous value to Pliant as

Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to Board of Directors

Mon, 13 Jul 2026 08:30:00 -0400

Appointments bring global oncology drug development experience
and deepen Board’s operational and regulatory expertise

Form 4 PLIANT THERAPEUTICS, For: Jun 11 Filed by: Cline Darren S